Advertisement

Two stage hepatectomy (TSH) versus ALPPS for initially unresectable colorectal liver metastases: A systematic review and meta-analysis

Published:November 08, 2022DOI:https://doi.org/10.1016/j.ejso.2022.11.010

      Abstract

      Background

      Although numerous comparisons between conventional Two Stage Hepatectomy (TSH) and Associating Liver Partition and Portal Vein Ligation for staged hepatectomy (ALPPS) have been reported, the heterogeneity of malignancies previously compared represents an important source of selection bias. This systematic review and meta-analysis aimed to compare perioperative and oncological outcomes between TSH and ALPPS to treat patients with initially unresectable colorectal liver metastases (CRLM).

      Methods

      Main electronic databases were searched using medical subject headings for CRLM surgically treated with TSH or ALPPS. Patients treated for primary or secondary liver malignancies other than CRLM were excluded.

      Results

      A total of 335 patients from 5 studies were included. Postoperative major complications were higher in the ALPPS group (relative risk [RR] 1.46, 95% confidence interval [CI] 1.04–2.06, I2 = 0%), while no differences were observed in terms of perioperative mortality (RR 1.53, 95% CI 0.64–3.62, I2 = 0%). ALPPS was associated with higher completion of hepatectomy rates (RR 1.32, 95% CI 1.09–1.61, I2 = 85%), as well as R0 resection rates (RR 1.61, 95% CI 1.13–2.30, I2 = 40%). Nevertheless, no significant differences were achieved between groups in terms of overall survival (OS) (RR 0.93, 95% CI 0.68–1.27, I2 = 52%) and disease-free survival (DFS) (RR 1.08, 95% CI 0.47–2.49, I2 = 54%), respectively.

      Conclusion

      ALPPS and TSH to treat CRLM seem to have comparable operative risks in terms of mortality rates. No definitive conclusions regarding OS and DFS can be drawn from the results.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • House M.G.
        • Ito H.
        • Gönen M.
        • Fong Y.
        • Allen P.J.
        • De Matteo R.P.
        • et al.
        Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.
        J Am Coll Surg. 2010; 210: 744-752
        • Hackl C.
        • Neumann P.
        • Gerken M.
        • Loss M.
        • Klinkhammer-Schalke M.
        • Schlitt H.J.
        Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma.
        BMC Cancer. 2014; 14: 810
        • Ye L.C.
        • Liu T.S.
        • Ren L.
        • Wei Y.
        • Zhu D.X.
        • Zai S.Y.
        • et al.
        Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
        J Clin Oncol. 2013; 31: 1931-1938
        • Folprecht G.
        • Gruenberger T.
        • Bechstein W.
        • Raab H.R.
        • Weitz J.
        • Lordick F.
        • et al.
        Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
        Ann Oncol. 2014; 25: 1018-1025
        • Köhne C.H.
        • Poston G.
        • Folprecht G.
        • Ciardiello F.
        • Ronga P.
        • Beier F.
        • et al.
        FOLFIRI plus cetuximab in patients with liver-limited or nonliver-limited RAS wild-type metastatic colorectal cancer: a retrospective subgroup analysis of the CRYSTAL study.
        Eur J Surg Oncol. 2016; 42: 1540-1547
        • Uetake H.
        • Yasuno M.
        • Ishiguro M.
        • Kameoka S.
        • Shimada Y.
        • Takahashi K.
        • et al.
        A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
        Ann Surg Oncol. 2015; 22: 908-915
        • Rouyer M.
        • Smith D.
        • Laurent C.
        • Becouarn Y.
        • Guimbaud R.
        • Michel P.
        • et al.
        ETNA study group. Secondary metastases resection after bevacizumab plus irinotecan-based chemotherapy in first-line therapy of metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.
        Targeted Oncol. 2016; 11: 83-92
        • Modest D.P.
        • Denecke T.
        • Pratschke J.
        • Ricard I.
        • Lang H.
        • Bemelmans M.
        • et al.
        Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
        Eur J Cancer. 2018; 88: 77-86
        • Jones R.P.
        • Hamann S.
        • Malik H.Z.
        • Fenwick S.W.
        • Poston G.J.
        • Folprecht G.
        Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer.
        Eur J Cancer. 2014; 50: 1590-1601
        • Jones R.P.
        • Vauthey J.N.
        • Adam R.
        • Rees M.
        • Berry D.
        • Jackson R.
        • et al.
        Effect of specialist decision-making on treatment strategies for colorectal liver metastases.
        Br J Surg. 2012; 99: 1263-1269
        • Bismuth H.
        • Adam R.
        • Lévi F.
        • Farabos C.
        • Waechter F.
        • Castaing D.
        • et al.
        Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.
        Ann Surg. 1996; 224: 509-520
        • Makuuchi M.
        • Thai B.L.
        • Takayasu K.
        • Takayama T.
        • Kosuge T.
        • Gunvén P.
        • et al.
        Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report.
        Surgery. 1990; 107: 521-527
        • Jaeck D.
        • Oussoultzoglou E.
        • Rosso E.
        • Greget M.
        • Weber J.C.
        • Bachellier P.
        A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases.
        Ann Surg. 2004; 240: 1037-1049
        • Adam R.
        • Laurent A.
        • Azoulay D.
        • Castaing D.
        • Bismuth H.
        Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors.
        Ann Surg. 2000; 232: 777-785
        • Brouquet A.
        • Abdalla E.K.
        • Kopetz S.
        • Garrett C.R.
        • Overman M.J.
        • Eng C.
        • et al.
        High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome.
        J Clin Oncol. 2011; 29: 1083-1090
        • Pandanaboyana S.
        • Bell R.
        • Hidalgo E.
        • Toogood G.
        • Prasad K.R.
        • Bartlett A.
        • et al.
        A systematic review and metaanalysis of portal vein ligation versus portal vein embolization for elective liver resection.
        Surgery. 2015; 157: 690-698
        • Simoneau E.
        • Hassanain M.
        • Shaheen M.
        • Aljiffry M.
        • Molla N.
        • Chaudhury P.
        • et al.
        Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases.
        Br J Surg. 2015; 102: 1240-1249
        • Giuliante F.
        • Ardito F.
        • Ferrero A.
        • Aldrighetti L.
        • Ercolani G.
        • Grande G.
        • et al.
        Tumor progression during preoperative chemotherapy predicts failure to complete 2-stage hepatectomy for colorectal liver metastases: results of an Italian multicenter analysis of 130 patients.
        J Am Coll Surg. 2014; 219: 285-294
        • Baumgart J.
        • Lang S.
        • Lang H.
        A new method for induction of liver hypertrophy prior to right trisectionectomy: a report of three cases.
        HPB. 2011; 13: 1-145
        • Schnitzbauer A.A.
        • Lang S.A.
        • Goessmann H.
        • Nadalin S.
        • Baumgart J.
        • Farkas S.A.
        • et al.
        Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.
        Ann Surg. 2012; 255: 405-414
        • Schadde E.
        • Ardiles V.
        • Robles-Campos R.
        • Malago M.
        • Machado M.
        • Hernandez-Alejandro R.
        • et al.
        • ALPPS Registry group
        Early survival and safety of ALPPS: first report of the International ALPPS Registry.
        Ann Surg. 2014; 260: 829-836
        • Raptis D.A.
        • Linecker M.
        • Kambakamba P.
        • Tschuor C.
        • Müller P.C.
        • Hadjittofi C.
        • et al.
        Defining benchmark outcomes for ALPPS.
        Ann Surg. 2019; 270: 835-841
        • Grąt M.
        • Hołówko W.
        • Lewandowski Z.
        • Kornasiewicz O.
        • Barski K.
        • Skalski M.
        • et al.
        Early post-operative prediction of morbidity and mortality after a major liver resection for colorectal metastases.
        HPB. 2013; 15: 352-358
        • Pearse R.M.
        • Moreno R.P.
        • Bauer P.
        • Pelosi P.
        • Metnitz P.
        • Spies C.
        • et al.
        European surgical outcomes study (EuSOS) group for the trials groups of the European society of intensive care medicine and the European society of anaesthesiology. Mortality after surgery in europe: a 7 day cohort study.
        Lancet. 2012; 380: 1059-1065
        • Schadde E.
        • Ardiles V.
        • Slankamenac K.
        • Tschuor C.
        • Sergeant G.
        • Amacker N.
        • et al.
        ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis.
        World J Surg. 2014; 38: 1510-1519
        • Croome K.P.
        • Hernandez-Alejandro R.
        • Parker M.
        • Heimbach J.
        • Rosen C.
        • Nagorney D.M.
        Is the liver kinetic growth rate in ALPPS unprecedented when compared with PVE and living donor liver transplant? A multicentre analysis.
        HPB. 2015; 17: 477-484
        • Tanaka K.
        • Matsuo K.
        • Murakami T.
        • Kawaguchi D.
        • Hiroshima Y.
        • Koda K.
        • et al.
        Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): short-term outcome, functional changes in the future liver remnant, and tumor growth activity.
        Eur J Surg Oncol. 2015; 41: 506-512
        • Shindoh J.
        • Vauthey J.N.
        • Zimmitti G.
        • Curley S.A.
        • Huang S.Y.
        • Mahvash A.
        • et al.
        Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach.
        J Am Coll Surg. 2013; 217: 126-133
        • Moher D.
        • Shamseer L.
        • Clarke M.
        • Ghersi D.
        • Liberati A.
        • Petticrew M.
        • et al.
        • PRISMA-P Group
        Preferred reporting items for systematic review and meta-analysis protocols (PRIMSA-P) 2015 statement.
        Syst Rev. 2015; 4: 1
        • Jadad A.R.
        • Moore R.A.
        • Carroll D.
        • Jenkinson C.
        • Reynolds D.J.
        • Gavaghan D.J.
        • et al.
        Assessing the quality of reports of randomized clinical trials: is blinding necessary?.
        Contr Clin Trials. 1996; 17: 1-12
        • Wells G.
        • Shea B.
        • O'Connell D.
        • Peterson J.
        • Welch V.
        • Losos M.
        • et al.
        The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
        Ottawa Hospital Research Institute, Ottawa, ON, Canada2000
        • Core Team
        R: a language and environment for statistical computing.
        R Foundation for Statistical Computing, Vienna, Austria2020 (URL)
        • Balduzzi S.
        • Rücker G.
        • Schwarzer G.
        How to perform a meta-analysis with R: a practical tutorial.
        Evid Base Ment Health. 2019; 22: 153-160
      1. Prospero international prospective register of systematic reviews.
        (Available online:)
        https://www.crd.york.ac.uk/PROSPERO/
        Date accessed: February 19, 2019
        (registered on 24 April 2019)
        • Sandström P.
        • Rosok B.I.
        • Sparrelid E.
        • Larsen P.N.
        • Larsson A.L.
        • Lindell G.
        • et al.
        ALPPS improves resectability compared with conventional two-staged hepatectomy in patients with advanced colorectal liver metastases. Results from a Scandinavian multicenter randomized controlled trial (LIGRO trial).
        Ann Surg. 2018; 267: 833-840
        • Ratti F.
        • Schadde E.
        • Masetti M.
        • Massani M.
        • Zanello M.
        • Serenari M.
        • et al.
        Strategies to increase the resectability of patients with colorectal liver metastases: a multi-center case-match analysis of ALPPS and conventional two-stage hepatectomy.
        Ann Surg Oncol. 2015; 22: 1933-1942
        • Adam R.
        • Imai K.
        • Castro Benitez C.
        • Allard M.A.
        • Vibert E.
        • Sa Cunha A.
        • et al.
        Outcome after associating liver partition and portal vein ligation for staged hepatectomy and conventional two-stage hepatectomy for colorectal liver metastases.
        Br J Surg. 2016; 103: 1521-1529
        • Kambakamba P.
        • Linecker M.
        • Alvarez F.A.
        • Samaras P.
        • Reiner C.S.
        • Raptis D.A.
        • et al.
        Short chemotherapy-free interval improves oncological outcome in patients undergoing two-stage hepatectomy for colorectal liver metastases.
        Ann Surg Oncol. 2016; 23: 3915-3923
        • Baumgart J.
        • Jungmann F.
        • Bartsch F.
        • Kloth M.
        • Mittler J.
        • Heinrich S.
        • et al.
        Two-staged hepatectomy and ALPPS for advanced bilateral liver metastases: a tailored approach balancing risk and outcome.
        J Gastrointest Surg. 2019; 23: 2391-2400
        • Chia D.K.A.
        • Yeo Z.
        • Loh S.E.K.
        • Iyer S.G.
        • Bonney G.K.
        • Madhavan K.
        • et al.
        Greater hypertrophy can be achieved with associating liver partition with portal vein ligation for staged hepatectomy compared to conventional staged hepatectomy, but with a higher price to pay?.
        Am J Surg. 2018; 215: 131-137
        • Matsuo K.
        • Murakami T.
        • Kawaguchi D.
        • Hiroshima Y.
        • Koda K.
        • Yamazaki K.
        • et al.
        Histologic features after surgery associating liver partition and portal vein ligation for staged hepatectomy versus those after hepatectomy with portal vein embolization.
        Surgery. 2016; 159: 1289-1298
        • Abulkhir A.
        • Limongelli P.
        • Healey A.
        • Damrah O.
        • Tait P.
        • Jackson J.
        • et al.
        Preoperative portal vein embolization for major liver resection: a meta-analysis.
        Ann Surg. 2008; 247: 49-57
        • Rahbari N.N.
        • Garden O.J.
        • Padbury R.
        • Brooke-Smith M.
        • Crawford M.
        • Adam R.
        • et al.
        Posthepatectomy liver failure: a definition and grading by the international study group of liver surgery (ISGLS).
        Surgery. 2011; 149: 713-724
        • Zorzi D.
        • Laurent A.
        • Pawlik T.M.
        • Lauwers G.Y.
        • Vauthey J.N.
        • Abdalla E.K.
        Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
        Br J Surg. 2007; 94: 274-286
        • Kremer M.
        • Manzini G.
        • Hristov B.
        • Polychronidis G.
        • Mokry T.
        • Sommer C.M.
        • et al.
        Impact of neoadjuvant chemotherapy on hypertrophy of the future liver remnant after associating liver partition and portal vein ligation for staged hepatectomy.
        J Am Coll Surg. 2015; 221: 717-728
        • Hasselgren K.
        • Malago M.
        • Vyas S.
        • Campos R.R.
        • Brusadin R.
        • Linecker M.
        • et al.
        Neoadjuvant chemotherapy does not affect future liver remnant growth and outcomes of associating liver partition and portal vein ligation for staged hepatectomy.
        Surgery. 2017; 161: 1255-1265
        • Croome K.P.
        • Hernandez-Alejandro R.
        • Parker M.
        • Heimbach J.
        • Rosen C.
        • Nagorney D.M.
        Is the liver kinetic growth rate in ALPPS unprecedented when compared with PVE and living donor liver transplant? A multicentre analysis.
        HPB. 2015; 17: 477-484
        • Kambakamba P.
        • Linecker M.
        • Schneider M.
        • Reiner C.S.
        • Nguyen-Kim T.D.L.
        • Limani P.
        • et al.
        Impact of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) on growth of colorectal liver metastases.
        Surgery. 2018; 163: 311-317
        • Lam V.W.
        • Laurence J.M.
        • Johnston E.
        • Hollands M.J.
        • Pleass H.C.
        • Richardson A.J.
        A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases.
        HPB. 2013; 15: 483-491
        • Imai K.
        • Benitez C.C.
        • Allard M.A.
        • Vibert E.
        • Cunha A.S.
        • Cherqui D.
        • et al.
        Failure to achieve a 2-stage hepatectomy for colorectal liver metastases: how to prevent it?.
        Ann Surg. 2015; 262: 772-778
        • Aloia T.A.
        • Vauthey J.N.
        Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): what is gained and what is lost?.
        Ann Surg. 2012; 256 (; author reply e16–e19): e9
        • Moris D.
        • Ronnekleiv-Kelly S.
        • Kostakis I.D.
        • Tsilimigras D.I.
        • Beal E.W.
        • Papalampros A.
        • et al.
        Operative results and oncologic outcomes of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus two-stage hepatectomy (TSH) in patients with unresectable colorectal liver metastases: a systematic review and meta-analysis.
        World J Surg. 2018; 42: 806-815
        • Knoefel W.T.
        • Gabor I.
        • Rehders A.
        • Alexander A.
        • Krausch M.
        • Schulte J.
        • et al.
        In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection.
        Br J Surg. 2013; 100: 388-394
        • Maupoey Ibáñez J.
        • Montalvá Orón E.M.
        • Robledo Boscà
        • et al.
        From conventional two-stage hepatectomy to ALPPS: fifteen years of experience in a hepatobiliary surgery unit.
        Hepatobiliary Pancreat Dis Int. 2021 Dec; 20: 542-550
        • Rosok B.I.
        • Host-Brunsell T.
        • Brudvik K.W.
        • Carling U.
        • Dorenberg E.
        • Björnsson B.
        • et al.
        Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver metastases and small future liver remnants; a translational substudy of the LIGRO-RCT.
        HPB. 2019; 21: 1017-1023
        • Hasselgren K.
        • Røsok B.I.
        • Larsen P.N.
        • Sparrelid E.
        • Lindell G.
        • Schultz N.A.
        • et al.
        ALPPS improves survival compared with TSH in patients affected of CRLM: survival analysis from the randomized controlled trial LIGRO.
        Ann Surg. 2021 Mar 1; 273: 442-448